F. Hoffmann-La Roche AG


About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.

Roche retains sole responsibility for content © 2021 F. Hoffmann-La Roche AG. All trademarks used or mentioned in this release are protected by law.

1 December 2019 - 30 November 2020

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 December 2019 - 30 November 2020 which are tracked by the Nature Index.

Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

Count Share
146 58.80

Outputs by subject (Share)

Subject Count Share
Life Sciences 118 41.64
Chemistry 34 19.67
Physical Sciences 2 0.74
1 0.19
1 0.56
Earth & Environmental Sciences 1 0.50

Highlight of the month

A hormone-mimicking weight-loss drug

© Felipe Caparrós Cruz/EyeEm/Getty Images

© Felipe Caparrós Cruz/EyeEm/Getty Images

An experimental drug designed to mimic a metabolic hormone is showing early promise as an anti-obesity treatment.

A team from Genentech, a Roche subsidiary, designed a bispecific antibody drug to bind and activate two receptors normally triggered by fibroblast growth factor 21 (FGF21), a hormone involved in regulating fat and sugar use.

The researchers first evaluated the drug in obese monkeys. A single injection caused profound weight loss, with marked reductions in food consumption to boot.

They next tested the therapy in 71 obese or overweight individuals, each of whom received a single injection of the drug or a placebo under the skin. The drug was well tolerated, improved blood measures of cardiometabolic health and, compared to the placebo, caused significant reductions in body weight. Both caloric intake and a desire for sweet foods decreased as well.

Roche is now investigating the drug in larger trials involving people with an advanced form of non-alcoholic fatty liver disease.

Supported content

  1. PNAS 117, 28992-29000 (2020). doi: 10.1073/pnas.2012073117

View the article on the Nature Index

See more research highlights from F. Hoffmann-La Roche AG

More research highlights from F. Hoffmann-La Roche AG

1 December 2019 - 30 November 2020

International vs. domestic collaboration by Share

  • 8.68% Domestic
  • 91.32% International

Note: Hover over the graph to view the percentage of collaboration.

Note: Collaboration is determined by the fractional count (Share), which is listed in parentheses.

Return to institution outputs